Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer

Lung Cancer

Volumn 83, Issue 3, 2014, Pages 329-333

  Kimura, Hideharu ^a   Ohira, Tatsuo ^b   Uchida, Osamu ^c   Matsubayashi, Jun ^b   Shimizu, Shinichiro ^c   Nagao, Toshitaka ^b   Ikeda, Norihiko ^b   Nishio, Kazuto ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c Funabashi Municipal Medical Center   (Japan)

Author keywords

Companion diagnostics; EGFR mutation; EGFR TKI treatment; Non small cell lung cancer; Personalised healthcare

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; GENOMIC DNA; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; COBAS EGFR ASSAY; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC KIT; DNA SEQUENCE; ENZYME ASSAY; EXON; FEMALE; GENETIC ANALYZER; HUMAN; HUMAN TISSUE; INDEL MUTATION; INTERMETHOD COMPARISON; JAPANESE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POINT MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; THERASCREEN EGFR ASSAY;

COBAS(®) EGFR MUTATION TEST; COMPANION DIAGNOSTICS; EGFR MUTATION; EGFR-TKI TREATMENT; NON-SMALL-CELL LUNG CANCER; PERSONALISED HEALTHCARE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC ERRORS; DNA; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MUTATION; REAGENT KITS, DIAGNOSTIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS;

EID: 84894265375     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.12.012     Document Type: Article

References (12)

1. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
2. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
3. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol 2012, 13:239-246.
4. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
5. Keedy V.L., Temin S., Somerfield M.R., Beasley M.B., Johnson D.H., McShane L.M., et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011, 29:2121-2127.
6. Lindeman N.I., Cagle P.T., Beasley M.B., Chitale D.A., Dacic S., Giaccone G., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013, (April). [Epub ahead of print].
7. Nguyen K.S., Kobayashi S., Costa D.B. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009, 10:281-289.
8. Fujita Y., Suda K., Kimura H., Matsumoto K., Arao T., Nagai T., et al. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol 2012, 7:1640-1644.
9. Yasuda H., Kobayashi S., Costa D.B. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012, 13:e23-e31.
10. Sharma S.V., Bell D.W., Settleman J., Haber D. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
11. Roche Molecular System Inc. cobas EGFR Mutation Test CE-IVD [Package Insert] 2011, Roche Molecular Systems Inc., Branchburg, NJ, USA.
12. QIAGEN Manchester Ltd. therascreen EGFR RGQ PCR Kit Handbook 2012.